Quality of life (QOL) has become an important outcome measure in the treatment of cancer patients. QOL mainly has been assessed in clinical trials within selective cancer populations to evaluate the effects of specific therapeutic procedures, whereas comparative analyses with QOL of population-based
Quality of Life in Breast Cancer Survivors as Identified by Focus Groups
β Scribed by Betty R. Ferrell; Marcia M. Grant; Brandi Funk; Shirley Otis-Green; Nellie Garcia
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 329 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1057-9249
No coin nor oath required. For personal study only.
β¦ Synopsis
Currently, over 1,700,000 women are living with breast cancer in the United States. These long-term survivors of breast cancer are challenged to redirect their energy from issues of cancer treatment and early side effects toward quality of life issues related to long-term survivorship, such as menopause, infertility, fear of recurrence, family distress, and uncertainty. In an attempt to obtain patient perspectives on quality of life and health care issues faced by breast cancer survivors, focus group methodology was utilized in the first year of a 2 year study. The sample was stratified to represent three age groups: < 40 years, 40-60 years, and > 60, and was intended to represent different developmental levels believed to have varying experiences with quality of life and potentially divergent needs following breast cancer diagnosis. Results of these focus groups revealed unique quality of life concerns of breast cancer survivors across four domains of physical, psychological, social, and spiritual well being. Each of these domains yields important implications for future research and clinical practice.
π SIMILAR VOLUMES
We report on our experience of quality of life (QL) assessment in adjuvant clinical trials of the International Breast Cancer Study Group (IBCSG), with special emphasis on cultural and logistical aspects of international organization that are unique to this group. Data are presented regarding submis
Quality of life (QOL) assessment has become an integrated part in some advanced disease trials and to a lesser extent in early disease trials conducted by the Swiss Group for Clinical Cancer Research (SAKK). In general, the concept of QOL endpoints and the additional work of collecting these data is